Methods for the early diagnosis of Parkinson's disease;Methoden zur frühdiagnose des morbus Parkinson

Nervenarzt

Volumn 74, Issue SUPPL. 1, 2003, Pages

  Becker, G ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Diagnosis; Gene mutations; Neuroprotective therapy; Parkinson's disease; Transcranial sonography

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; DIHYDROXYPHENYLALANINE F 18; DOPAMINE; NEUROLEPTIC AGENT; NEUROPROTECTIVE AGENT; RADIOISOTOPE; UNCLASSIFIED DRUG; AUTOANTIBODY; MELANIN; NEUROMELANIN;

ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DOPAMINERGIC SYSTEM; DOPPLER ECHOGRAPHY; GENE MUTATION; HUMAN; MOTOR DYSFUNCTION; NERVE CELL DEGENERATION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; RISK FACTOR; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BLOOD; COMPARATIVE STUDY; CORPUS STRIATUM; DIAGNOSTIC IMAGING; DRUG EFFECT; GENETICS; IMMUNOLOGY; METABOLISM; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; NUCLEOTIDE SEQUENCE; PATHOLOGY; SENSITIVITY AND SPECIFICITY; SUBSTANTIA NIGRA; TWINS;

AUTOANTIBODIES; CORPUS STRIATUM; DIAGNOSTIC IMAGING; DISEASES IN TWINS; DNA MUTATIONAL ANALYSIS; DOPAMINE; HUMANS; MELANINS; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; SENSITIVITY AND SPECIFICITY; SUBSTANTIA NIGRA;

EID: 3042750314     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-003-1482-9     Document Type: Article

References (39)

1. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20(4):415-455
2. Hornykiewicz O, Kish SJ (1987) Biochemical pathophysiology of Parkinson's disease. Adv Neurol 45:19-34
3. Langston JW, Koller WC (1991) Preclinical detection of Parkinson's disease. The next frontier: presymptomatic detection. Introduction. Geriatrics 46 [Suppl 1]:5-7
4. Forno LS (1969) Concentric hyalin intraneuronal inclusions of Lewy type in the brains of elderly persons (50 incidental cases): relationship to parkinsonism. J Am Geriatr Soc 17(6):557-575
5. Gibb WR (1986) Idiopathic Parkinson's disease and the Lewy body disorders. Neuropathol Appl Neurobiol 12(3):223-234
6. Asenbaum S, Brucke T, Pirker W et al. (1997) Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease. J Nucl Med 38(1):1-6
7. Morrish PK, Sawle GV, Brooks DJ (1995) Clinical and [18F] dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 59(6):597-600
8. Schwarz J, Linke R, Kerner M et al. (2000) Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: implications for a preclinical diagnosis. Arch Neurol 57(2):205-208
9. Burn DJ, Mark MH, Playford ED et al. (1992) Parkinson's disease in twins studied with 18F-dopa and positron emission tomography. Neurology 42(10):1894-1900
10. Laihinen A, Ruottinen H, Rinne JO et al. (2000) Risk for Parkinson's disease: twin studies for the detection of asymptomatic subjects using [18F]6-fluorodopa PET. J Neurol 247 [Suppl 2]:II110-II113
11. Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ (1999) The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 45(5):577-582
12. Hilker R, Klein C, Hedrich K et al. (2002) The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans. Neurosci Lett 323(1):50-54
13. Lee CS, Samii A, Sossi V et al. (2000) In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 47(4):493-503
14. Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K (1995) Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology 45(1):182-184
15. Berg D, Siefker C, Becker G (2001) Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol 248(8):684-689
16. Walter U, Wittstock M, Benecke R, Dressler D (2002) Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease. J Neural Transm 109(2):191-196
17. Berg D, Becker G, Zeiler B et al. (1999) Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 53(5):1026-1031
18. Berg D, Roggendorf W, Schroder U et al. (2002) Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59(6):999-1005
19. Snow BJ, Tooyama I, McGeer EG et al. (1993) Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 34(3):324-330
20. Berg D, Siefker C, Ruprecht-Dorfler P, Becker G (2001) Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology 56(1):13-17
21. Berg D, Jabs B, Merschdorf U, Beckmann H, Becker G (2001) Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy. Biol Psychiatry 50(6):463-467
22. Wakabayashi K, Takahashi H (1997) Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 38 [Suppl 2]:2-7
23. Braak E, Sandmann-Keil D, Rub U et al. (2001) Alpha-synuclein immunopositive Parkinson's disease-related inclusion bodies in lower brain stem nuclei. Acta Neuropathol (Berl) 101(3):195-201
24. Braak H, Braak E (2000) Pathoanatomy of Parkinson's disease. J Neurol 247 [Suppl 2]:II3-10
25. Braune S (2001) The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Auton Res 11(6):351-355
26. Doty RL, Deems DA, Stellar S (1988) Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 38(8):1237-1244
27. Doty RL, Golbe LI, McKeown DA, Stern MB, Lehrach CM, Crawford D (1993) Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson's disease. Neurology 43(5):962-965
28. Wenning GK, Shephard B, Hawkes C, Petruckevitch A, Lees A, Quinn N (1995) Olfactory function in atypical parkinsonian syndromes. Acta Neurol Scand 91(4):247-250
29. Tissingh G, Berendse HW, Bergmans P et al. (2001) Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis. Mov Disord 16(1):41-46
30. Berendse HW, Booij J, Francot CM et al. (2001) Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann Neurol 50(1):34-41
31. Cummings JL (1992) Depression and Parkinson's disease: a review. Am J Psychiatry 149(4):443-454
32. Mindham RH (1970) Psychiatric symptoms in Parkinsonism. J Neurol Neurosurg Psychiatry 33(2):188-191
33. Robins AH (1976) Depression in patients with Parkinsonism. Br J Psychiatry 128:141-145
34. Montgomery EB, Jr., Lyons K, Koller WC (2000) Early detection of probable idiopathic Parkinson's disease: II. A prospective application of a diagnostic test battery. Mov Disord 15(3):474-478
35. Montgomery EB Jr, Koller WC, LaMantia TJ et al. (2000) Early detection of probable idiopathic Parkinson's disease: I. Development of a diagnostic test battery. Mov Disord 15(3):467-473
36. Bodis-Wollner I, Onofrj M (1987) The visual system in Parkinson's disease. Adv Neurol 45:323-327
37. Buttner T, Kuhn W, Patzold T, Przuntek H (1994) L-Dopa improves colour vision in Parkinson's disease. J Neural Transm Park Dis Dement Sect 7(1):13-19
38. Buttner T, Kuhn W, Muller T, Patzold T, Heidbrink K, Przuntek H (1995) Distorted color discrimination in 'de novo' parkinsonian patients. Neurology 45(2):386-387
39. Price MJ, Feldman RG, Adelberg D, Kayne H (1992) Abnormalities in color vision and contrast sensitivity in Parkinson's disease. Neurology 42(4):887-890